Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Rubin, David; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter; Mishkin, Daniel; Arrisi, Pablo; Scalori, Astrid; Oh, Young; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panes, CAN

doi:10.1016/s2468-1253(21)00338-1

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Atıf İçin Kopyala

Rubin D. T., Dotan I., DuVall A., Bouhnik Y., Radford-Smith G., Higgins P. D. R., ...Daha Fazla

LANCET GASTROENTEROLOGY & HEPATOLOGY, cilt.7, sa.1, ss.17-27, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 1
Basım Tarihi: 2022
Doi Numarası: 10.1016/s2468-1253(21)00338-1
Dergi Adı: LANCET GASTROENTEROLOGY & HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.17-27
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background Etrolizumab is a gut-targeted anti-beta 7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis.